ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sandoz Buys Rights To Pfizer Biosimilar

by Ann M. Thayer
February 22, 2016 | APPEARED IN VOLUME 94, ISSUE 8

Sandoz, the generic drug arm of Novartis, has acquired rights to Pfizer’s biosimilar version of infliximab in 28 European countries. In 2015, Remicade, the brand-name version of the biologic, racked up $6.6 billion in sales for Johnson & Johnson. Infliximab is a TNF-α inhibitor used to treat autoimmune diseases such as rheumatoid arthritis and psoriasis. Sandoz must still complete Phase III clinical development and file for European regulatory approval of the biosimilar. Pfizer had to divest the program to win regulatory approval for its acquisition of Hospira.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment